Overview


According to FutureWise analysis the market for alzheimers disease diagnostics and therapeutics in 2023 is US$ 6.63 billion, and is expected to register a CAGR of 8.60% in 2023-2031.

Alzheimer's disease is a disorder that affects the brain and causes memory loss, cognitive decline, and changes in behaviour. Diagnosing Alzheimer's can be difficult, but doctors use a variety of methods such as medical history, physical exams, cognitive tests, and imaging techniques to eliminate other possible causes. Ongoing research aims to develop reliable biomarkers, such as beta-amyloid and tau proteins, that can aid in early detection and accurate diagnosis. These biomarkers can be detected in cerebrospinal fluid (CSF), blood samples, or through advanced brain imaging techniques. Additionally, efforts are underway to improve imaging technologies, such as positron emission tomography (PET) scans, to better visualize the characteristic brain changes associated with Alzheimer's.

Regarding therapeutics, available treatments for Alzheimer's disease focus on managing symptoms rather than addressing the underlying cause. Cholinesterase inhibitors and memantine are commonly prescribed medications that can temporarily improve cognitive function and delay symptom progression. However, researchers are actively investigating disease-modifying treatments that target the underlying mechanisms of Alzheimer's. These approaches include immunotherapies that aim to clear beta-amyloid plaques, tau-targeting drugs to prevent the formation of neurofibrillary tangles, and drugs that enhance neuronal function and synaptic health. Developing effective disease-modifying therapies remains a significant challenge, requiring extensive clinical trials and collaborations among researchers, clinicians, and pharmaceutical companies.

FutureWise Market Research has published a report that provides an insightful analysis of alzheimers disease diagnostics and therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that alzheimers disease diagnostics and therapeutics market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • H. Lundbeck A/S
  • ALLERGAN
  • TauRx
  • AC Immune
  • Johnson and Johnson
  • AbbVie Inc.
  • Eli Lilly and Company

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments by the Key Players in the Alzheimers Disease Diagnostics and Therapeutics Market:

  • In October 2022, The Phase 2b clinical trial of Trappsol Cyclo by Cyclo Therapeutics, Inc. has commenced, with the objective of treating Alzheimer's disease through the reduction of amyloid beta and tau. The Institutional Review Board (IRB) has approved the study.

The market for diagnosing and treating Alzheimer's disease is rapidly expanding due to several reasons including an aging population, greater awareness of the disease, advancements in medical technology, and ongoing research efforts. The diagnostics segment, in particular, has seen significant progress, with improved early detection techniques and the emergence of biomarkers and neuroimaging methods enabling more accurate diagnosis and disease monitoring. On the therapeutic front, researchers are actively pursuing disease-modifying treatments, with several promising drug candidates targeting different pathological aspects of Alzheimer's disease. Precision medicine and personalized treatment approaches are gaining popularity, and regulatory agencies are fast-tracking the approval process for novel therapies. Despite challenges like the high cost of clinical trials and ethical considerations, there are still immense opportunities for advancements and a hopeful outlook for effective treatments that can alleviate the burden of Alzheimer's disease on patients and society.

By Product Type

  • Therapeutics
  • Diagnostics

By End User

  • Hospitals
  • Clinics

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The market for Alzheimer's disease diagnostics and therapeutics is poised for substantial growth in North America. The region is home to a significant number of individuals affected by this debilitating disease, and with an aging population, the prevalence of Alzheimer's is expected to rise. At the same time, the research and development of new diagnostic tools and treatment options is receiving substantial investment, further fueling the growth of this market. As a result, we can anticipate continued expansion and innovation in the diagnosis and treatment of Alzheimer's disease in North America.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Alzheimers Disease Diagnostics and Therapeutics Market By Product Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Alzheimers Disease Diagnostics and Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alzheimers Disease Diagnostics and Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Alzheimers Disease Diagnostics and Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Alzheimers Disease Diagnostics and Therapeutics Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Therapeutics
        2. Diagnostics

  • 8.   Global Alzheimers Disease Diagnostics and Therapeutics Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics

  • 9.   North America Alzheimers Disease Diagnostics and Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Alzheimers Disease Diagnostics and Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Alzheimers Disease Diagnostics and Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Alzheimers Disease Diagnostics and Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Eisai Co., Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. H. Lundbeck A/S
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ALLERGAN
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. TauRx
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AC Immune
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson and Johnson
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. AbbVie Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Eli Lilly and Company
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Alzheimer’s Disease Diagnostic Market

Read More

Alzheimer's Disease Drug Market

Read More

Dementia Associated with Alzheimer Disease Market

Read More
Partner

Our Clients